Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Clot-Sucking catheter may boost heart attack outcomes

NCT ID NCT05510661

Disease control Sponsor: National Institute of Cardiovascular Diseases, Pakistan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares using a manual clot-removal catheter (Export) before standard balloon angioplasty versus angioplasty alone in 300 heart attack patients with completely blocked arteries. The goal is to see if removing the clot first improves blood flow and reduces in-hospital complications like heart failure or death. Results will help determine the best timing for clot removal during emergency procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Export catheter (thrombus aspiration device)
What this could lead to
If successful, this could show that removing blood clots before opening a blocked artery during a heart attack improves blood flow and reduces complications.
What could go wrong
This is a single-center trial with 300 participants, so results may not apply broadly. Previous studies on thrombus aspiration have shown mixed results, and the procedure carries risks like bleeding or vessel damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients presenting with:-Symptoms of myocardial ischemia lasting for ≥30 minutes * Definite ECG changes indicating STEMI: ST elevation of greater than 0.1 mV in two contiguous limb leads or 0.2 mV in two contiguous precordial leads * Chest pain \< 12 hours duration * Total occlusion (TIMI 0 flow) * Patients undergoing primary PCI * Informed consent Exclusion Criteria: * Patients with prior history of cardiac related surgery or intervention * Performance of a rescue PCI after thrombolysis * Known existence of a disease resulting in a life expectancy of less than 6 months * Killip class III, IV

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary percutaneous coronary intervention are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary stenosis ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary percutaneous coronary intervention ST-segment elevation myocardial infarction (stemi) Total occlusion of coronary artery

Contacts and locations

Locations

  • National Institute of Cardiovascular Diseases

    Karachi, Sindh, 75510, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.